Novate: Re-Newing The IVC Filter Market
Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.
You may also be interested in...
The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.